Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of ARGX-119 in adult participants with DOK7 Congenital Myasthenic Syndrome
2023-509872-41-00Phase 2Authorised
- Sponsor
- argenx
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, single-arm trial of adimanebart in congenital myasthenic syndrome (CMS), sponsored by argenx. Primary endpoint: Primary safety and tolerability. Planned start Sep 2024; status: authorised.
02
Drugs
adimanebart
03
Conditions
congenital myasthenic syndrome (CMS)
Beyond the preview
Go deeper on 2023-509872-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509872-41-00.